Quantcast

Impacts of the Human Gut Microbiome on Therapeutics.

Research paper by Yoshiki Y Vázquez-Baeza, Chris C Callewaert, Justine J Debelius, Embriette E Hyde, Clarisse C Marotz, James T JT Morton, Austin A Swafford, Alison A Vrbanac, Pieter C PC Dorrestein, Rob R Knight

Indexed on: 03 Oct '17Published on: 03 Oct '17Published in: Annual review of pharmacology and toxicology



Abstract

The human microbiome contains a vast source of genetic and biochemical variation, and its impacts on therapeutic responses are just beginning to be understood. This expanded understanding is especially important because the human microbiome differs far more among different people than does the human genome, and it is also dramatically easier to change. Here, we describe some of the major factors driving differences in the human microbiome among individuals and populations. We then describe some of the many ways in which gut microbes modify the action of specific chemotherapeutic agents, including nonsteroidal anti-inflammatory drugs and cardiac glycosides, and outline the potential of fecal microbiota transplant as a therapeutic. Intriguingly, microbes also alter how hosts respond to therapeutic agents through various pathways acting at distal sites. Finally, we discuss some of the computational and practical issues surrounding use of the microbiome to stratify individuals for drug response, and we envision a future where the microbiome will be modified to increase everyone's potential to benefit from therapy. Expected final online publication date for the Annual Review of Pharmacology and Toxicology Volume 58 is January 6, 2018. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.